Literature DB >> 22835143

Advances in modulating thermosensory TRP channels.

Antonio Ferrer-Montiel1, Asia Fernández-Carvajal, Rosa Planells-Cases, Gregorio Fernández-Ballester, José Manuel González-Ros, Angel Messeguer, Rosario González-Muñiz.   

Abstract

INTRODUCTION: Thermosensory channels are a subfamily of the transient receptor potential (TRP) channel family that are activated by changes in the environmental temperature. These channels, known as thermoTRPs, cover the entire spectrum of temperatures, from noxious cold (< 15°C) to injurious heat (> 42°C). In addition, dysfunction of these channels contributes to the thermal hypersensitivity that accompanies painful conditions. Moreover, because of their wide tissue and cellular distribution, thermoTRPs are also involved in the pathophysiology of several diseases, from inflammation to cancer. AREAS COVERED: Although the number of thermoTRPs is increasing with the identification of novel members such as TRPM3, we will cover the recent advances in the pharmacology of the classical thermosensory channels, namely TRPV1, TRPV2, TRPV3, TRPV4, TRPM8 and TRPA1. This review will focus on the therapeutic progress carried out for all these channels and will highlight the tenet that TRPV1, TRPM8 and TRPA1 are the most exploited channels, and that the interest on TRPV3 and TRPV4 is growing with the first TRPV3 antagonist that moves into Phase-II clinical trials. In contrast, the pharmacology of TRPV2 is yet in its infancy. EXPERT OPINION: Despite the tremendous academic and industrial investment to develop therapeutic modulators of thermoTRPs, it apparently seems that we are still far from the first successful product, although hope is maintained high for all compounds currently in clinical trials. A major concern has been the appearance of side effects. A better knowledge of the thermosensory protein networks (signal-plexes), along with the application of system biology approaches may provide novel strategies to modulate thermoTRPs activity with improved therapeutic index. A case in point is TRPV1, where acting on interacting proteins is providing new therapeutic opportunities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22835143     DOI: 10.1517/13543776.2012.711320

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  26 in total

Review 1.  TRPing on the pore phenomenon: what do we know about transient receptor potential ion channel-related pore dilation up to now?

Authors:  L G B Ferreira; R X Faria
Journal:  J Bioenerg Biomembr       Date:  2016-01-04       Impact factor: 2.945

Review 2.  TRPV3: time to decipher a poorly understood family member!

Authors:  Bernd Nilius; Tamás Bíró; Grzegorz Owsianik
Journal:  J Physiol       Date:  2013-07-08       Impact factor: 5.182

3.  Examination of the role of transient receptor potential vanilloid type 4 in endothelial responses to shear forces.

Authors:  Sara Baratchi; Francisco J Tovar-Lopez; Khashayar Khoshmanesh; Megan S Grace; William Darby; Juhura Almazi; Arnan Mitchell; Peter McIntyre
Journal:  Biomicrofluidics       Date:  2014-08-15       Impact factor: 2.800

Review 4.  Potential therapeutic value of transient receptor potential channels in male urogenital system.

Authors:  Gamze Toktanis; Ecem Kaya-Sezginer; Didem Yilmaz-Oral; Serap Gur
Journal:  Pflugers Arch       Date:  2018-09-07       Impact factor: 3.657

5.  TRPV4 Antagonists: Potential Treatment for Congestive Heart Failure, Bladder Dysfunctions, and Pain.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2013-01-23       Impact factor: 4.345

6.  Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1 channels.

Authors:  Luciano De Petrocellis; Aniello Schiano Moriello; Gabriele Fontana; Alessandro Sacchetti; Daniele Passarella; Giovanni Appendino; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 7.  What do we know about the transient receptor potential vanilloid 2 (TRPV2) ion channel?

Authors:  Alex Perálvarez-Marín; Pau Doñate-Macian; Rachelle Gaudet
Journal:  FEBS J       Date:  2013-05-28       Impact factor: 5.542

8.  Olmsted syndrome with oral involvement, including premature teeth loss.

Authors:  Ahmed K Alotaibi; Mazen K Alotaibi; Suliman Alsaeed; Ahmad Alyahya; Charles F Shuler
Journal:  Odontology       Date:  2014-01-29       Impact factor: 2.634

9.  Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways.

Authors:  Zhizheng Zhao; Huiting Fan; Tim Higgins; Jia Qi; Diana Haines; Anna Trivett; Joost J Oppenheim; Hou Wei; Jie Li; Hongsheng Lin; O M Zack Howard
Journal:  Cancer Lett       Date:  2014-09-19       Impact factor: 8.679

10.  The combination of TRPM8 and TRPA1 expression causes an invasive phenotype in lung cancer.

Authors:  Gang-Jun Du; Jia-Huan Li; Wei-Jie Liu; Ying-Hui Liu; Bei Zhao; Hong-Ru Li; Xi-Dong Hou; Hong Li; Xiao-Xiao Qi; Yong-Jian Duan
Journal:  Tumour Biol       Date:  2013-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.